Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m
The divestment is part of Takeda’s strategy to focus on core business areas and facilitate rapid deleveraging following its acquisition of Shire. Takeda growth and emerging markets business
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.